ADORA2A and gastric cancer: Combination Therapy: AB928 (dual A2AR/A2BR antagonist) combined with anti-PD-1 (Zimberelimab) achieved an ORR of 35% in the GC subgroup, with a median progression-free survival (PFS) of 8.2 months.